Published: 5 May 2021
Authors: Gunn Marit Traaen, Lars Aakerøy, Tove-Elizabeth Hunt, Britt Øverland, Christina Bendz, Lars Øivind Sande, Svend Aakhus, Morten Wang Fagerland, Sigurd Steinshamn, Ole-Gunnar Anfinsen, Richard John Massey, Kaspar Broch, Thor Ueland, Harriet Akre, Jan Pål Loennechen and Lars Gullestad
Source: This abstract has been sourced from NZ Respiratory Research Review Issue 197
Rationale: Sleep apnea (SA) is highly prevalent in patients with atrial fibrillation (AF), and both conditions are associated with adverse cardiovascular outcomes.
Objectives: To determine the effect of continuous positive airway pressure (CPAP) on AF burden.
Methods: This open-label, parallel-group, randomized controlled trial included patients with paroxysmal AF and moderate to severe SA (apnea–hypopnea index ⩾15). A computerized system randomized eligible patients (1:1) to 5 months’ treatment with CPAP plus usual care (CPAP, n = 55) or usual care alone (control, n = 54). The outcome assessment was blinded. The planned primary outcome was the difference between CPAP treatment and control groups in change of AF burden (percentage of time in AF) as measured by implantable loop recorder.
Measurements and Main Results: A total of 579 patients with paroxysmal AF had respiratory polygraphy, of whom 244 (42%) had moderate to severe SA. Of these, 158 (65%) participated in the CPAP run-in period, of whom 39 (25%) patients did not tolerate the treatment. A total of 108 patients were available for the primary analysis. The mean time in AF decreased from 5.6% at baseline to 4.1% during the last 3 months of CPAP intervention and from 5.0% to 4.3% in the control group. The adjusted between-group difference at follow-up was −0.63 (95% confidence interval, −2.55 to 1.30) percentage points (P = 0.52). Seven serious adverse events (13%) occurred in the CPAP group, and two (4%) occurred in the control group.
Conclusions: In patients with paroxysmal AF and SA, treatment with CPAP did not result in a statistically significant reduction in the burden of AF.Clinical trial registered with www.clinicaltrials.gov (NCT02727192).
Link to abstract
NZ Respiratory Research Review Issue 197